Document:

ARRAYIT DIAGNOSTICS, INC.

2009 DIRECTORS, OFFICERS AND CONSULTANTS

STOCK OPTION, STOCK WARRANT AND STOCK AWARD PLAN

 

SECTION 1. PURPOSE OF THE PLAN. The purpose of the 2009 Directors,
Officers and Consultants Stock Option, Stock Warrant and Stock Award Plan ("Plan") is to maintain the ability of Arrayit
Diagnostics, Inc., a Nevada corporation (the "Company") and its subsidiaries to attract and retain highly qualified and
experienced directors, employees and consultants and to give such directors, employees and consultants a continued proprietary
interest in the success of the Company and its subsidiaries. In addition the Plan is intended to encourage ownership of common
stock, $.001 par value ("Common Stock"), of the Company by the directors, employees and consultants of the Company and
its Affiliates (as defined below) and to provide increased incentive for such persons to render services and to exert maximum effort
for the success of the Company's business. The Plan provides eligible employees and consultants the opportunity to participate
in the enhancement of shareholder value by the grants of warrants, options, restricted common or convertible preferred stock, unrestricted
common or convertible preferred stock and other awards under this Plan and to have their bonuses and/or consulting fees payable
in warrants, restricted common or convertible preferred stock, unrestricted common or convertible preferred stock and other awards,
or any combination thereof. In addition, the Company expects that the Plan will further strengthen the identification of the directors,
employees and consultants with the stockholders. Certain options and warrants to be granted under this Plan are intended to qualify
as Incentive Stock Options ("ISOs") pursuant to Section 422 of the Internal Revenue Code of 1986, as amended ("Code"),
while other options and warrants and preferred stock granted under this Plan will be nonqualified options or warrants which are
not intended to qualify as ISOs ("Nonqualified Options"), either or both as provided in the agreements evidencing the
options or warrants described in Section 5 hereof and shares of preferred stock. As provided in the designation described in Section

7. Employees, consultants and directors who participate or become eligible to participate in this Plan from time to time are referred
to collectively herein as "Participants". As used in this Plan, the term "Affiliates" means any "parent
corporation" of the Company and any "subsidiary corporation" of the Company within the meaning of Code Sections
424(e) and (f), respectively.

 

SECTION 2. ADMINISTRATION OF THE PLAN.

 

(a) Composition of Committee. The Plan shall be administered
by the Board of Directors of the Company (the "Board"). When acting in such capacity the Board is herein referred to
as the "Committee," which shall also designate the Chairman of the Committee. If the Company is governed by Rule 16b-3
promulgated by the Securities and Exchange Commission ("Commission") pursuant to the Securities Exchange Act of 1934,
as amended ("Exchange Act"), no director shall serve as a member of the Committee unless he or she is a "disinterested
person" within the meaning of such Rule 16b-3.

 

(b) Committee Action. The Committee shall hold its meetings
at such times and places as it may determine. A majority of its members shall constitute a quorum, and all determinations of the
Committee shall be made by not less than a majority of its members. Any decision or determination reduced to writing and signed
by a majority of the members shall be fully as effective as if it had been made by a majority vote of its members at a meeting
duly called and held. The Committee may designate the Secretary of the Company or other Company employees to assist the Committee
in the administration of the Plan, and may grant authority to such persons to execute award agreements or other documents on behalf
of the Committee and the Company. Any duly constituted committee of the Board satisfying the qualifications of this Section 2 may
be appointed as the Committee.

 

(c) Committee Expenses. All expenses and liabilities incurred
by the Committee in the administration of the Plan shall be borne by the Company. The Committee may employ attorneys, consultants,
accountants or other persons.

 

    	1

    	 

    
 

SECTION 3. STOCK RESERVED FOR THE PLAN. Subject to adjustment
as provided in Section 5(d)(xiii) hereof, the aggregate number of shares that may be optioned, subject to conversion or issued
under the Plan is 12,000,000 shares of Common Stock, warrants, options, preferred stock or any combination thereof. The shares
subject to the Plan shall consist of authorized but unissued shares of Common Stock and such number of shares shall be and is hereby
reserved for sale for such purpose. Any of such shares which may remain unsold and which are not subject to issuance upon exercise
of outstanding options or warrants or conversion of outstanding shares of preferred stock at the termination of the Plan shall
cease to be reserved for the purpose of the Plan, but until termination of the Plan or the termination of the last of the options
or warrants granted under the Plan, whichever last occurs, the Company shall at all times reserve a sufficient number of shares
to meet the requirements of the Plan. Should any option or warrant expire or be cancelled prior to its exercise in full, the shares
theretofore subject to such option or warrant may again be made subject to an option, warrant or shares of convertible preferred
stock under the Plan.

 

Immediately upon the grant of any option, warrant, shares of
preferred stock or award, the number of shares of Common Stock that may be issued or optioned under the Plan will be increased.
The number of shares of such increase shall be an amount such that immediately after such increase the total number of shares issuable
under the Plan and reserved for issuance upon exercise of outstanding options, warrants or conversion of shares of preferred stock
will equal 15% of the total number of issued and outstanding shares of Common Stock of the Company. Such increase in the number
of shares subject to the Plan shall occur without the necessity of any further corporate action of any kind or character.

 

SECTION 4. ELIGIBILITY. The Participants shall include directors,
employees, including officers, of the Company and its divisions and subsidiaries, and consultants and attorneys who provide bona
fide services to the Company. Participants are eligible to be granted warrants, options, restricted common or convertible preferred
stock, unrestricted common or convertible preferred stock and other awards under this Plan and to have their bonuses and/or consulting
fees payable in warrants, restricted common or convertible preferred stock, unrestricted common or convertible preferred stock
and other awards. A Participant who has been granted an option, warrant or preferred stock hereunder may be granted an additional
option, warrant options, warrants or preferred stock, if the Committee shall so determine.

 

SECTION 5. GRANT OF OPTIONS OR WARRANTS.

 

(a) Committee Discretion. The Committee shall have sole and
absolute discretionary authority (i) to determine, authorize, and designate those persons pursuant to this Plan who are to receive
warrants, options, restricted common or convertible preferred stock, or unrestricted common or convertible preferred stock under
the Plan, (ii) to determine the number of shares of Common Stock to be covered by such grant or such options or warrants and the
terms thereof, (iii) to determine the type of Common Stock granted: restricted common or convertible preferred stock, unrestricted
common or convertible preferred stock or a combination of restricted and unrestricted common or convertible preferred stock, and
(iv) to determine the type of option or warrant granted: ISO, Nonqualified Option or a combination of ISO and Nonqualified Options.
The Committee shall thereupon grant options or warrants in accordance with such determinations as evidenced by a written option
or warrant agreement. Subject to the express provisions of the Plan, the Committee shall have discretionary authority to prescribe,
amend and rescind rules and regulations relating to the Plan, to interpret the Plan, to prescribe and amend the terms of the option
or warrant agreements (which need not be identical) and to make all other determinations deemed necessary or advisable for the
administration of the Plan.

 

(b) Stockholder Approval. All ISOs granted under this Plan are
subject to, and may not be exercised before, the approval of this Plan by the stockholders prior to the first anniversary date
of the Board meeting held to approve the Plan, by the affirmative vote of the holders of a majority of the outstanding shares of
the Company present, or represented by proxy, and entitled to vote thereat, or by written consent in accordance with the laws of
the State of Nevada, provided that if such approval by the stockholders of the Company is not forthcoming, all options or warrants
and stock awards previously granted under this Plan other than ISOs shall be valid in all respects.

 

(c) Limitation on Incentive Stock Options and Warrants. The
aggregate fair market value (determined in accordance with Section 5(d)(ii) of this Plan at the time the option or warrant is granted)
of the Common Stock with respect to which ISOs may be exercisable for the first time by any Participant during any calendar year
under all such plans of the Company and its Affiliates shall not exceed $3,000,000.

 

(d) Terms and Conditions. Each option or warrant granted under
the Plan shall be evidenced by an agreement, in a form approved by the Committee, which shall be subject to the following express
terms and conditions and to such other terms and conditions as the Committee may deem appropriate:

 

    	2

    	 

    
 

(i) Option or Warrant Period. The Committee shall promptly notify
the Participant of the option or warrant grant and a written agreement shall promptly be executed and delivered by and on behalf
of the Company and the Participant, provided that the option or warrant grant shall expire if a written agreement is not signed
by said Participant (or his agent or attorney) and returned to the Company within 60 days from date of receipt by the Participant
of such agreement. The date of grant shall be the date the option or warrant is actually granted by the Committee, even though
the written agreement may be executed and delivered by the Company and the Participant after that date. Each option or warrant
agreement shall specify the period for which the option or warrant thereunder is granted (which in no event shall exceed ten years
from the date of grant) and shall provide that the option or warrant shall expire at the end of such period. If the original term
of an option or warrant is less than ten years from the date of grant, the option or warrant may be amended prior to its expiration,
with the approval of the Committee and the Participant, to extend the term so that the term as amended is not more than ten years
from the date of grant. However, in the case of an ISO granted to an individual who, at the time of grant, owns stock possessing
more than 10 percent of the total combined voting power of all classes of stock of the Company or its Affiliate ("Ten Percent
Stockholder"), such period shall not exceed five years from the date of grant.

 

(ii) Option or Warrant Price. The purchase price of each share
of Common Stock subject to each option or warrant granted pursuant to the Plan shall be determined by the Committee at the time
the option or warrant is granted and, in the case of ISOs, shall not be less than 100% of the fair market value of a share of Common
Stock on the date the option or warrant is granted, as determined by the Committee. In the case of an ISO granted to a Ten Percent
Stockholder, the option or warrant price shall not be less than 110% of the fair market value of a share of Common Stock on the
date the option or warrant is granted. The purchase price of each share of Common Stock subject to a Nonqualified Option or Warrant
under this Plan shall be determined by the Committee prior to granting the option or warrant. The Committee shall set the purchase
price for each share subject to a Nonqualified Option or Warrant at either the fair market value of each share on the date the
option or warrant is granted, or at such other price as the Committee in its sole discretion shall determine.

 

At the time a determination of the fair market value of a share
of Common Stock is required to be made hereunder, the determination of its fair market value shall be made by the Committee in
such manner as it deems appropriate.

 

(iii) Exercise Period. The Committee may provide in the option
or warrant agreement that an option or warrant may be exercised in whole, immediately, or is to be exercisable in increments. In
addition, the Committee may provide that the exercise of all or part of an option or warrant is subject to specified performance
by the Participant.

 

(iv) Procedure for Exercise. Options or warrants shall be exercised
in the manner specified in the option or warrant agreement. The notice of exercise shall specify the address to which the certificates
for such shares are to be mailed. A Participant shall be deemed to be a stockholder with respect to shares covered by an option
or warrant on the date specified in the option or warrant agreement . As promptly as practicable, the Company shall deliver to
the Participant or other holder of the warrant, certificates for the number of shares with respect to which such option or warrant
has been so exercised, issued in the holder's name or such other name as holder directs; provided, however, that such delivery
shall be deemed effected for all purposes when a stock transfer agent of the Company shall have deposited such certificates with
a carrier for overnight delivery, addressed to the holder at the address specified pursuant to this

Section 6(d).

 

(v) Termination of Employment. If an executive officer to whom
an option or warrant is granted ceases to be employed by the Company for any reason other than death or disability, any option
or warrant which is exercisable on the date of such termination of employment may be exercised during a period beginning on such
date and ending at the time set forth in the option or warrant agreement; provided, however, that if a Participant's employment
is terminated because of the Participant's theft or embezzlement from the Company, disclosure of trade secrets of the Company or
the commission of a willful, felonious act while in the employment of the Company (such reasons shall hereinafter be collectively
referred to as "for cause"), then any option or warrant or unexercised portion thereof granted to said Participant shall
expire upon such termination of employment. Notwithstanding the foregoing, no ISO may be exercised later than three months after
an employee's termination of employment for any reason other than death or disability.

 

    	3

    	 

    
 

(vi) Disability or Death of Participant. In the event of the
determination of disability or death of a Participant under the Plan while he or she is employed by the Company, the options or
warrants previously granted to him may be exercised (to the extent he or she would have been entitled to do so at the date of the
determination of disability or death) at any time and from time to time, within a period beginning on the date of such determination
of disability or death and ending at the time set forth in the option or warrant agreement, by the former employee, the guardian
of his estate, the executor or administrator of his estate or by the person or persons to whom his rights under the option or warrant
shall pass by will or the laws of descent and distribution, but in no event may the option or warrant be exercised after its expiration
under the terms of the option or warrant agreement. Notwithstanding the foregoing, no ISO may be exercised later than one year
after the determination of disability or death. A Participant shall be deemed to be disabled if, in the opinion of a physician
selected by the Committee, he or she is incapable of performing services for the Company of the kind he or she was performing at
the time the disability occurred by reason of any medically determinable physical or mental impairment which can be expected to
result in death or to be of long, continued and indefinite duration. The date of determination of disability for purposes hereof
shall be the date of such determination by such physician.

 

(vii) Assignability. An option or warrant shall be assignable
or otherwise transferable, in whole or in part, by a Participant as provided in the option, warrant or designation of the series
of preferred stock.

 

(viii) Incentive Stock Options. Each option or warrant agreement
may contain such terms and provisions as the Committee may determine to be necessary or desirable in order to qualify an option
or warrant designated as an incentive stock option.

 

(ix) Restricted Stock Awards. Awards of restricted stock under
this Plan shall be subject to all the applicable provisions of this Plan, including the following terms and conditions, and to
such other terms and conditions not inconsistent therewith, as the Committee shall determine:

 

(A) Awards of restricted stock may be in addition to or in lieu
of option or warrant grants. Awards may be conditioned on the attainment of particular performance goals based on criteria established
by the Committee at the time of each award of restricted stock. During a period set forth in the agreement (the "Restriction
Period"), the recipient shall not be permitted to sell, transfer, pledge, or otherwise encumber the shares of restricted stock;
except that such shares may be used, if the agreement permits, to pay the option or warrant price pursuant to any option or warrant
granted under this Plan, provided an equal number of shares delivered to the Participant shall carry the same restrictions as the
shares so used. Shares of restricted stock shall become free of all restrictions if during the Restriction Period, (i) the recipient
dies, (ii) the recipient's directorship, employment, or consultancy terminates by reason of permanent disability, as determined
by the Committee, (iii) the recipient retires after attaining both 59 1/2 years of age and five years of continuous service with
the Company and/or a division or subsidiary, or (iv) if provided in the agreement, there is a "change in control" of
the Company (as defined in such agreement). The Committee may require medical evidence of permanent disability, including medical
examinations by physicians selected by it. Unless and to the extent otherwise provided in the agreement, shares of restricted stock
shall be forfeited and revert to the Company upon the recipient's termination of directorship, employment or consultancy during
the Restriction Period for any reason other than death, permanent disability, as determined by the Committee, retirement after
attaining both 59 1/2 years of age and five years of continuous service with the Company and/or a subsidiary or division, or, to
the extent provided in the agreement, a "change in control" of the Company (as defined in such agreement), except to
the extent the Committee, in its sole discretion, finds that such forfeiture might not be in the best interests of the Company
and, therefore, waives all or part of the application of this provision to the restricted stock held by such recipient. Certificates
for restricted stock shall be registered in the name of the recipient but shall be imprinted with the appropriate legend and returned
to the Company by the recipient, together with a stock power endorsed in blank by the recipient. The recipient shall be entitled
to vote shares of restricted stock and shall be entitled to all dividends paid thereon, except that dividends paid in Common Stock
or other property shall also be subject to the same restrictions.

 

(B) Restricted Stock shall become free of the foregoing restrictions
upon expiration of the applicable Restriction Period and the Company shall then deliver to the recipient Common Stock certificates
evidencing such stock. Restricted stock and any Common Stock received upon the expiration of the restriction period shall be subject
to such other transfer restrictions and/or legend requirements as are specified in the applicable agreement.

 

    	4

    	 

    
 

(x) Bonuses and Past Salaries and Fees Payable in Unrestricted
Stock.

 

(A) In lieu of cash bonuses otherwise payable under the Company's
or applicable division's or subsidiary's compensation practices to employees and consultants eligible to participate in this Plan,
the Committee, in its sole discretion, may determine that such bonuses shall be payable in unrestricted Common Stock or partly
in unrestricted Common Stock and partly in cash. Such bonuses shall be in consideration of services previously performed and as
an incentive toward future services and shall consist of shares of unrestricted Common Stock subject to such terms as the Committee
may determine in its sole discretion. The number of shares of unrestricted Common Stock payable in lieu of a bonus otherwise payable
shall be determined by dividing such bonus amount by the fair market value of one share of Common Stock on the date the bonus is
payable, with fair market value determined as of such date in accordance with Section 5(d)(ii).

 

(B) In lieu of salaries and fees otherwise payable by the Company
to employees, attorneys and consultants eligible to participate in this Plan that were incurred for services rendered during, prior
or after the year of 2009, the Committee, in its sole discretion, may determine that such unpaid salaries and fees shall be payable
in unrestricted Common Stock or partly in unrestricted Common Stock and partly in cash. Such awards shall be in consideration of
services previously performed and as an incentive toward future services and shall consist of shares of unrestricted Common Stock
subject to such terms as the Committee may determine in its sole discretion. The number of shares of unrestricted Common Stock
payable in lieu of a salaries and fees otherwise payable shall be determined by dividing each calendar month's of unpaid salary
or fee amount by the average trading value of the Common Stock for the calendar month during which the subject services were provided.

 

(xi) No Rights as Stockholder. No Participant shall have any
rights as a stockholder with respect to shares covered by an option or warrant until the option or warrant is exercised as provided
in clause

(d) above.

 

(xii) Extraordinary Corporate Transactions. The existence of
outstanding options or warrants shall not affect in any way the right or power of the Company or its stockholders to make or authorize
any or all adjustments, recapitalizations, reorganizations, exchanges, or other changes in the Company's capital structure or its
business, or any merger or consolidation of the Company, or any issuance of Common Stock or other securities or subscription rights
thereto, or any issuance of bonds, debentures, preferred or prior preference stock ahead of or affecting the Common Stock or the
rights thereof, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business,
or any other corporate act or proceeding, whether of a similar character or otherwise. If the Company recapitalizes or otherwise
changes its capital structure, or merges, consolidates, sells all of its assets or dissolves (each of the foregoing a "Fundamental
Change"), then thereafter upon any exercise of an option or warrant theretofore granted the Participant shall be entitled
to purchase under such option or warrant, in lieu of the number of shares of Common Stock as to which option or warrant shall then
be exercisable, the number and class of shares of stock and securities to which the Participant would have been entitled pursuant
to the terms of the Fundamental Change if, immediately prior to such Fundamental Change, the Participant had been the holder of
record of the number of shares of Common Stock as to which such option or warrant is then exercisable. If (i) the Company shall
not be the surviving entity in any merger or consolidation (or survives only as a subsidiary of another entity), (ii) the Company
sells all or substantially all of its assets to any other person or entity (other than a wholly-owned subsidiary), (iii) any person
or entity (including a "group" as contemplated by Section 13(d)(3) of the Exchange Act) acquires or gains ownership or
control of (including, without limitation, power to vote) more than 50% of the outstanding shares of Common Stock, (iv) the Company
is to be dissolved and liquidated, or (v) as a result of or in connection with a contested election of directors, the persons who
were directors of the Company before such election shall cease to constitute a majority of the Board (each such event in clauses
(i) through (v) above is referred to herein as a "Corporate Change"), the Committee, in its sole discretion, may accelerate
the time at which all or a portion of a Participant's option or warrants may be exercised for a limited period of time before or
after a specified date.

 

(xiii) Changes in Company's Capital Structure. If the outstanding
shares of Common Stock or other securities of the Company, or both, for which the option or warrant is then exercisable at any
time be changed or exchanged by declaration of a stock dividend, stock split, combination of shares, recapitalization, or reorganization,
the number and kind of shares of Common Stock or other securities which are subject to the Plan or subject to any options or warrants
theretofore granted, and the option or warrant prices, shall be adjusted only as provided in the option or warrant.

 

    	5

    	 

    
 

(xiv) Acceleration of Options and Warrants. Except as hereinbefore
expressly provided, (i) the issuance by the Company of shares of stock or any class of securities convertible into shares of stock
of any class, for cash, property, labor or services, upon direct sale, upon the exercise of rights or warrants to subscribe therefor,
or upon conversion of shares or obligations of the Company convertible into such shares or other securities, (ii) the payment of
a dividend in property other than Common Stock or (iii) the occurrence of any similar transaction, and in any case whether or not
for fair value, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number of shares of Common
Stock subject to options or warrants theretofore granted or the purchase price per share, unless the Committee shall determine,
in its sole discretion, that an adjustment is necessary to provide equitable treatment to Participant. Notwithstanding anything
to the contrary contained in this Plan, the Committee may, in its sole discretion, accelerate the time at which any option or warrant
may be exercised, including, but not limited to, upon the occurrence of the events specified in this Section 5, and is authorized
at any time (with the consent of the Participant) to purchase options or warrants pursuant to Section 6.

 

SECTION 6. RELINQUISHMENT OF OPTIONS OR WARRANTS.

 

(a) The Committee, in granting options or warrants hereunder,
shall have discretion to determine whether or not options or warrants shall include a right of relinquishment as hereinafter provided
by this Section 6. The Committee shall also have discretion to determine whether an option or warrant agreement evidencing an option
or warrant initially granted by the Committee without a right of relinquishment shall be amended or supplemented to include such
a right of relinquishment. Neither the Committee nor the Company shall be under any obligation or incur any liability to any person
by reason of the Committee's refusal to grant or include a right of relinquishment in any option or warrant granted hereunder or
in any option or warrant agreement evidencing the same. Subject to the Committee's determination in any case that the grant by
it of a right of relinquishment is consistent with Section 1 hereof, any option or warrant granted under this Plan, and the option
or warrant agreement evidencing such option or warrant, may provide:

 

(i) That the Participant, or his or her heirs or other legal
representatives to the extent entitled to exercise the option or warrant under the terms thereof, in lieu of purchasing the entire
number of shares subject to purchase thereunder, shall have the right to relinquish all or any part of the then unexercised portion
of the option or warrant (to the extent then exercisable) for a number of shares of Common Stock to be determined in accordance
with the following provisions of this clause (i):

 

(A) The written notice of exercise of such right of relinquishment
shall state the percentage of the total number of shares of Common Stock issuable pursuant to such relinquishment (as defined below)
that the Participant elects to receive;

 

(B) The number of shares of Common Stock, if any, issuable pursuant
to such relinquishment shall be the number of such shares, rounded to the next greater number of full shares, as shall be equal
to the quotient obtained by dividing

(i) the Appreciated Value by (ii) the purchase price for each of such shares specified in such option or warrant;

 

(C) For the purpose of this clause (C), "Appreciated Value"
means the excess, if any, of (x) the total current market value of the shares of Common Stock covered by the option or warrant
or the portion thereof to be relinquished over (y) the total purchase price for such shares specified in such option or warrant;

 

(ii) That such right of relinquishment may be exercised only
upon receipt by the Company of a written notice of such relinquishment which shall be dated the date of election to make such relinquishment;
and that, for the purposes of this Plan, such date of election shall be deemed to be the date when such notice is sent by registered
or certified mail, or when receipt is acknowledged by the Company, if mailed by other than registered or certified mail or if delivered
by hand or by any telegraphic communications equipment of the sender or otherwise delivered; provided, that, in the event the method
just described for determining such date of election shall not be or remain consistent with the provisions of Section 16(b) of
the Exchange Act or the rules and regulations adopted by the Commission thereunder, as presently existing or as may be hereafter
amended, which regulations exempt from the operation of Section 16(b) of the Exchange Act in whole or in part any such relinquishment
transaction, then such date of election shall be determined by such other method consistent with

Section 16(b) of the Exchange Act or the rules and regulations thereunder as the Committee shall in its discretion select and apply;

 

    	6

    	 

    
 

(iii) That the "current market value" of a share of
Common Stock on a particular date shall be deemed to be its fair market value on that date as determined in accordance with Paragraph
5(d)(ii); and

 

(iv) That the option or warrant, or any portion thereof, may
be relinquished only to the extent that (A) it is exercisable on the date written notice of relinquishment is received by the Company,
and (B) the holder of such option or warrant pays, or makes provision satisfactory to the Company for the payment of, any taxes
which the Company is obligated to collect with respect to such relinquishment.

 

(b) The Committee shall have sole discretion to consent to or
disapprove, and neither the Committee nor the Company shall be under any liability by reason of the Committee's disapproval of,
any election by a holder of preferred stock to relinquish such preferred stock in whole or in part as provided in Paragraph 7(a),
except that no such consent to or approval of a relinquishment shall be required under the following circumstances. Each Participant
who is subject to the short-swing profits recapture provisions of Section 16(b) of the Exchange Act ("Covered Participant") shall not be entitled to receive shares of Common Stock when
options or warrants are relinquished during any window period commencing on the third business day following the Company's release
of a quarterly or annual summary statement of sales and earnings and ending on the twelfth business day following such release
("Window Period"). A Covered Participant shall be entitled to receive shares of Common Stock upon the relinquishment
of options or warrants outside a Window Period.

 

(c) The Committee, in granting options or warrants hereunder,
shall have discretion to determine the terms upon which such options or warrants shall be relinquishable, subject to the applicable
provisions of this Plan, and including such provisions as are deemed advisable to permit the exemption from the operation from
Section 16(b) of the Exchange Act of any such relinquishment transaction, and options or warrants outstanding, and option agreements
evidencing such options, may be amended, if necessary, to permit such exemption. If options or warrants are relinquished, such
option or warrant shall be deemed to have been exercised to the extent of the number of shares of Common Stock covered by the option
or warrant or part thereof which is relinquished, and no further options or warrants may be granted covering such shares of Common
Stock.

 

(d) Any options or warrants or any right to relinquish the same
to the Company as contemplated by this Paragraph 6 shall be assignable by the Participant, provided the transaction complies with
any applicable securities laws.

 

(e) Except as provided in Section 6(f) below, no right of relinquishment
may be exercised within the first six months after the initial award of any option or warrant containing, or the amendment or supplementation
of any existing option or warrant agreement adding, the right of relinquishment.

 

(f) No right of relinquishment may be exercised after the initial
award of any option or warrant containing, or the amendment or supplementation of any existing option or warrant agreement adding
the right of relinquishment, unless such right of relinquishment is effective upon the Participant's death, disability or termination
of his relationship with the Company for a reason other than "for cause."

 

SECTION 7. GRANT OF CONVERTIBLE PREFERRED STOCK.

 

(a) Committee Discretion. The Committee shall have sole and
absolute discretionary authority (i) to determine, authorize, and designate those persons pursuant to this Plan who are to receive
restricted preferred stock, or unrestricted preferred stock under the Plan, and (ii) to determine the number of shares of Common
Stock to be issued upon conversion of such shares of preferred stock and the terms thereof. The Committee shall thereupon grant
shares of preferred stock in accordance with such determinations as evidenced by a written preferred stock designation. Subject
to the express provisions of the Plan, the Committee shall have discretionary authority to prescribe, amend and rescind rules and
regulations relating to the Plan, to interpret the Plan, to prescribe and amend the terms of the preferred stock designation (which
need not be identical) and to make all other determinations deemed necessary or advisable for the administration of the Plan.

 

    	7

    	 

    
 

(b) Terms and Conditions. Each series of preferred stock granted
under the Plan shall be evidenced by a designation in the form for filing with the Secretary of State of the state of incorporation
of the Company, containing such terms as approved by the Committee, which shall be subject to the following express terms and conditions
and to such other terms and conditions as the Committee may deem appropriate:

 

(i) Conversion Ratio. The number of shares of Common Stock issuable
upon conversion of each share of preferred stock granted pursuant to the Plan shall be determined by the Committee at the time
the preferred stock is granted. The conversion ration may be determined by reference to the fair market value of each share of
Common Stock on the date the preferred stock is granted, or at such other price as the Committee in its sole discretion shall determine.

 

At the time a determination of the fair market value of a share
of Common Stock is required to be made hereunder, the determination of its fair market value shall be made in accordance with Paragraph
5(d)(ii).

 

(ii) Conversion Period. The Committee may provide in the preferred
stock agreement that an preferred stock may be converted in whole, immediately, or is to be convertible in increments. In addition,
the Committee may provide that the conversion of all or part of an preferred stock is subject to specified performance by the Participant.

 

(iii) Procedure for Conversion. Shares of preferred stock shall
be converted in the manner specified in the preferred stock designation. The notice of conversion shall specify the address to
which the certificates for such shares are to be mailed. A Participant shall be deemed to be a stockholder with respect to shares
covered by preferred stock on the date specified in the preferred stock agreement. As promptly as practicable, the Company shall deliver to the Participant or other holder of the warrant, certificates for the
number of shares with respect to which such preferred stock has been so converted, issued in the holder's name or such other name
as holder directs; provided, however, that such delivery shall be deemed effected for all purposes when a stock transfer agent
of the Company shall have deposited such certificates with a carrier for overnight delivery, addressed to the holder at the address
specified pursuant to this

Section 6(d).

 

(iv) Termination of Employment. If an executive officer to whom
preferred stock is granted ceases to be employed by the Company for any reason other than death or disability, any preferred stock
which is convertible on the date of such termination of employment may be converted during a period beginning on such date and
ending at the time set forth in the preferred stock agreement; provided, however, that if a Participant's employment is terminated
because of the Participant's theft or embezzlement from the Company, disclosure of trade secrets of the Company or the commission
of a willful, felonious act while in the employment of the Company (such reasons shall hereinafter be collectively referred to
as "for cause"), then any preferred stock or unconverted portion thereof granted to said Participant shall expire upon
such termination of employment. Notwithstanding the foregoing, no ISO may be converted later than three months after an employee's
termination of employment for any reason other than death or disability.

 

(v) Disability or Death of Participant. In the event of the
determination of disability or death of a Participant under the Plan while he or she is employed by the Company, the preferred
stock previously granted to him may be converted (to the extent he or she would have been entitled to do so at the date of the
determination of disability or death) at any time and from time to time, within a period beginning on the date of such determination
of disability or death and ending at the time set forth in the preferred stock agreement, by the former employee, the guardian
of his estate, the executor or administrator of his estate or by the person or persons to whom his rights under the preferred stock
shall pass by will or the laws of descent and distribution, but in no event may the preferred stock be converted after its expiration
under the terms of the preferred stock agreement. Notwithstanding the foregoing, no ISO may be converted later than one year after
the determination of disability or death. A Participant shall be deemed to be disabled if, in the opinion of a physician selected
by the Committee, he or she is incapable of performing services for the Company of the kind he or she was performing at the time
the disability occurred by reason of any medically determinable physical or mental impairment which can be expected to result in
death or to be of long, continued and indefinite duration. The date of determination of disability for purposes hereof shall be
the date of such determination by such physician.

 

(vi) Assignability. Preferred stock shall be assignable or otherwise
transferable, in whole or in part, by a Participant.

 

    	8

    	 

    
 

(vii) Restricted Stock Awards. Awards of restricted preferred
stock under this Plan shall be subject to all the applicable provisions of this Plan, including the following terms and conditions,
and to such other terms and conditions not inconsistent therewith, as the Committee shall determine:

 

(A) Awards of restricted preferred stock may be in addition
to or in lieu of preferred stock grants. Awards may be conditioned on the attainment of particular performance goals based on criteria
established by the Committee at the time of each award of restricted preferred stock. During a period set forth in the agreement
(the "Restriction Period"), the recipient shall not be permitted to sell, transfer, pledge, or otherwise encumber the
shares of restricted preferred stock. Shares of restricted preferred stock shall become free of all restrictions if during the
Restriction Period, (i) the recipient dies, (ii) the recipient's directorship, employment, or consultancy terminates by reason
of permanent disability, as determined by the Committee, (iii) the recipient retires after attaining both 59 1/2 years of age and
five years of continuous service with the Company and/or a division or subsidiary, or (iv) if provided in the agreement, there
is a "change in control" of the Company (as defined in such agreement). The Committee may require medical evidence of
permanent disability, including medical examinations by physicians selected by it. Unless and to the extent otherwise provided
in the agreement, shares of restricted preferred stock shall be forfeited and revert to the Company upon the recipient's termination
of directorship, employment or consultancy during the Restriction Period for any reason other than death, permanent disability,
as determined by the Committee, retirement after attaining both 59 1/2 years of age and five years of continuous service with the
Company and/or a subsidiary or division, or, to the extent provided in the agreement, a "change in control" of the Company
(as defined in such agreement), except to the extent the Committee, in its sole discretion, finds that such forfeiture might not
be in the best interests of the Company and, therefore, waives all or part of the application of this provision to the restricted
preferred stock held by such recipient. Certificates for restricted preferred stock shall be registered in the name of the recipient
but shall be imprinted with the appropriate legend and returned to the Company by the recipient, together with a preferred stock
power endorsed in blank by the recipient. The recipient shall be entitled to vote shares of restricted preferred stock and shall
be entitled to all dividends paid thereon, except that dividends paid in Common Stock or other property shall also be subject to
the same restrictions.

 

(B) Restricted preferred stock shall become free of the foregoing
restrictions upon expiration of the applicable Restriction Period and the Company shall then deliver to the recipient Common Stock
certificates evidencing such stock. Restricted preferred stock and any Common Stock received upon the expiration of the restriction
period shall be subject to such other transfer restrictions and/or legend requirements as are specified in the applicable agreement.

 

(x) Bonuses and Past Salaries and Fees Payable in Unrestricted
Preferred stock.

 

(A) In lieu of cash bonuses otherwise payable under the Company's
or applicable division's or subsidiary's compensation practices to employees and consultants eligible to participate in this Plan,
the Committee, in its sole discretion, may determine that such bonuses shall be payable in unrestricted Common Stock or partly
in unrestricted Common Stock and partly in cash. Such bonuses shall be in consideration of services previously performed and as
an incentive toward future services and shall consist of shares of unrestricted Common Stock subject to such terms as the Committee
may determine in its sole discretion. The number of shares of unrestricted Common Stock payable in lieu of a bonus otherwise payable
shall be determined by dividing such bonus amount by the fair market value of one share of Common Stock on the date the bonus is
payable, with fair market value determined as of such date in accordance with Section 5(d)(ii).

 

(B) In lieu of salaries and fees otherwise payable by the Company
to employees, attorneys and consultants eligible to participate in this Plan that were incurred for services rendered during, prior
or after the year of 2009, the Committee, in its sole discretion, may determine that such unpaid salaries and fees shall be payable
in unrestricted Common Stock or partly in unrestricted Common Stock and partly in cash. Such awards shall be in consideration of
services previously performed and as an incentive toward future services and shall consist of shares of unrestricted Common Stock
subject to such terms as the Committee may determine in its sole discretion. The number of shares of unrestricted Common Stock
payable in lieu of a salaries and fees otherwise payable shall be determined by dividing each calendar month's of unpaid salary
or fee amount by the average trading value of the Common Stock for the calendar month during which the subject services were provided.

 

    	9

    	 

    
 

(xi) No Rights as Stockholder. No Participant shall have any
rights as a stockholder with respect to shares covered by an preferred stock until the preferred stock is converted as provided
in clause

(b)(iii) above.

 

(xii) Extraordinary Corporate Transactions. The existence of
outstanding preferred stock shall not affect in any way the right or power of the Company or its stockholders to make or authorize
any or all adjustments, recapitalizations, reorganizations, exchanges, or other changes in the Company's capital structure or its
business, or any merger or consolidation of the Company, or any issuance of Common Stock or other securities or subscription rights
thereto, or any issuance of bonds, debentures, preferred or prior preference stock ahead of or affecting the Common Stock or the
rights thereof, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business,
or any other corporate act or proceeding, whether of a similar character or otherwise. If the Company recapitalizes or otherwise
changes its capital structure, or merges, consolidates, sells all of its assets or dissolves (each of the foregoing a "Fundamental
Change"), then thereafter upon any conversion of preferred stock theretofore granted the Participant shall be entitled to
the number of shares of Common Stock upon conversion of such preferred stock, in lieu of the number of shares of Common Stock as
to which preferred stock shall then be convertible, the number and class of shares of stock and securities to which the Participant
would have been entitled pursuant to the terms of the Fundamental Change if, immediately prior to such Fundamental Change, the
Participant had been the holder of record of the number of shares of Common Stock as to which such preferred stock is then convertible.
If (i) the Company shall not be the surviving entity in any merger or consolidation (or survives only as a subsidiary of another
entity), (ii) the Company sells all or substantially all of its assets to any other person or entity (other than a wholly-owned
subsidiary), (iii) any person or entity (including a "group" as contemplated by Section 13(d)(3) of the Exchange Act)
acquires or gains ownership or control of (including, without limitation, power to vote) more than 50% of the outstanding shares
of Common Stock, (iv) the Company is to be dissolved and liquidated, or (v) as a result of or in connection with a contested election
of directors, the persons who were directors of the Company before such election shall cease to constitute a majority of the Board
(each such event in clauses (i) through (v) above is referred to herein as a "Corporate Change"), the Committee, in its
sole discretion, may accelerate the time at which all or a portion of a Participant's shares of preferred stock may be converted
for a limited period of time before or after a specified date.

 

(xiii) Changes in Company's Capital Structure. If the outstanding
shares of Common Stock or other securities of the Company, or both, for which the preferred stock is then convertible at any time
be changed or exchanged by declaration of a stock dividend, stock split, combination of shares, recapitalization, or reorganization,
the number and kind of shares of Common Stock or other securities which are subject to the Plan or subject to any preferred stock
theretofore granted, and the conversion ratio, shall be adjusted only as provided in the designation of the preferred stock.

 

(xiv) Acceleration of Conversion of Preferred Stock. Except
as hereinbefore expressly provided, (i) the issuance by the Company of shares of stock or any class of securities convertible into
shares of stock of any class, for cash, property, labor or services, upon direct sale, upon the conversion of rights or warrants
to subscribe therefor, or upon conversion of shares or obligations of the Company convertible into such shares or other securities,
(ii) the payment of a dividend in property other than Common Stock or (iii) the occurrence of any similar transaction, and in any
case whether or not for fair value, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number
of shares of Common Stock subject to preferred stock theretofore granted, unless the Committee shall determine, in its sole discretion,
that an adjustment is necessary to provide equitable treatment to Participant. Notwithstanding anything to the contrary contained
in this Plan, the Committee may, in its sole discretion, accelerate the time at which any preferred stock may be converted, including,
but not limited to, upon the occurrence of the events specified in this Section 7(xiv).

 

SECTION 8. AMENDMENTS OR TERMINATION. The Board may amend, alter
or discontinue the Plan, but no amendment or alteration shall be made which would impair the rights of any Participant, without
his consent, under any option, warrant or preferred stock theretofore granted.

 

    	10

    	 

    
 

SECTION 9. COMPLIANCE WITH OTHER LAWS AND REGULATIONS. The Plan,
the grant and exercise of options or warrants and grant and conversion of preferred stock thereunder, and the obligation of the
Company to sell and deliver shares under such options, warrants or preferred stock, shall be subject to all applicable federal
and state laws, rules and regulations and to such approvals by any governmental or regulatory agency as may be required. The Company
shall not be required to issue or deliver any certificates for shares of Common Stock prior to the completion of any registration
or qualification of such shares under any federal or state law or issuance of any ruling or regulation of any government body which
the Company shall, in its sole discretion, determine to be necessary or advisable. Any adjustments provided for in subparagraphs
5(d)(xii), (xiii) and (xiv) shall be subject to any shareholder action required by the corporate law of the state of incorporation
of the Company.

 

SECTION 10. PURCHASE FOR INVESTMENT. Unless the options, warrants,
shares of convertible preferred stock and shares of Common Stock covered by this Plan have been registered under the Securities
Act of 1933, as amended, or the Company has determined that such registration is unnecessary, each person acquiring or exercising
an option or warrant under this Plan or converting shares of preferred stock may be required by the Company to give a representation
in writing that he or she is acquiring such option or warrant or such shares for his own account for investment and not with a
view to, or for sale in connection with, the distribution of any part thereof.

 

SECTION 11. TAXES.

 

(a) The Company may make such provisions as it may deem appropriate
for the withholding of any taxes which it determines is required in connection with any options, warrants or preferred stock granted
under this Plan.

 

(b) Notwithstanding the terms of Paragraph 11 (a), any Participant
may pay all or any portion of the taxes required to be withheld by the Company or paid by him or her in connection with the exercise
of a nonqualified option or warrant or conversion of preferred stock by electing to have the Company withhold shares of Common
Stock, or by delivering previously owned shares of Common Stock, having a fair market value, determined in accordance with Paragraph
5(d)(ii), equal to the amount required to be withheld or paid. A Participant must make the foregoing election on or before the
date that the amount of tax to be withheld is determined ("Tax Date"). All such elections are irrevocable and subject
to disapproval by the Committee. Elections by Covered Participants are subject to the following additional restrictions: (i) such
election may not be made within six months of the grant of an option or warrant, provided that this limitation shall not apply
in the event of death or disability, and (ii) such election must be made either six months or more prior to the Tax Date or in
a Window Period. Where the Tax Date in respect of an option or warrant is deferred until six months after exercise and the Covered
Participant elects share withholding, the full amount of shares of Common Stock will be issued or transferred to him upon exercise
of the option or warrant, but he or she shall be unconditionally obligated to tender back to the Company the number of shares necessary
to discharge the Company's withholding obligation or his estimated tax obligation on the Tax Date.

 

SECTION 12. REPLACEMENT OF OPTIONS, WARRANTS AND PREFERRED STOCK.
The Committee from time to time may permit a Participant under the Plan to surrender for cancellation any unexercised outstanding
option or warrant or unconverted Preferred stock and receive from the Company in exchange an option, warrant or preferred stock
for such number of shares of Common Stock as may be designated by the Committee. The Committee may, with the consent of the holder
of any outstanding option, warrant or preferred stock, amend such option, warrant or preferred stock, including reducing the exercise
price of any option or warrant to not less than the fair market value of the Common Stock at the time of the amendment, increasing
the conversion ratio of any preferred stock and extending the exercise or conversion term of and warrant, option or preferred stock.

 

SECTION 13. NO RIGHT TO COMPANY EMPLOYMENT. Nothing in this
Plan or as a result of any option or warrant granted pursuant to this Plan shall confer on any individual any right to continue
in the employ of the Company or interfere in any way with the right of the Company to terminate an individual's employment at any
time. The option, warrant or preferred stock agreements may contain such provisions as the Committee may approve with reference
to the effect of approved leaves of absence.

 

SECTION 14. LIABILITY OF COMPANY. The Company and any Affiliate
which is in existence or hereafter comes into existence shall not be liable to a Participant or other persons as to:

 

(a) The Non-Issuance of Shares. The non-issuance or sale of
shares as to which the Company has been unable to obtain from any regulatory body having jurisdiction the authority deemed by the
Company's counsel to be necessary to the lawful issuance and sale of any shares hereunder; and

 

    	11

    	 

    
 

(b) Tax Consequences. Any tax consequence expected, but not
realized, by any Participant or other person due to the exercise of any option or warrant or the conversion of any preferred stock
granted hereunder.

 

SECTION 15. EFFECTIVENESS AND EXPIRATION OF PLAN. The Plan shall
be effective on the date the Board adopts the Plan. The Plan shall expire ten years after the date the Board approves the Plan
and thereafter no option, warrant or preferred stock shall be granted pursuant to the Plan.

 

SECTION 16. NON-EXCLUSIVITY OF THE PLAN. Neither the adoption
by the Board nor the submission of the Plan to the stockholders of the Company for approval shall be construed as creating any
limitations on the power of the Board to adopt such other incentive arrangements as it may deem desirable, including without limitation,
the granting of restricted stock or stock options, warrants or preferred stock otherwise than under the Plan, and such arrangements
may be either generally applicable or applicable only in specific cases.

 

SECTION 17. GOVERNING LAW. This Plan and any agreements hereunder
shall be interpreted and construed in accordance with the laws of the state of incorporation of the Company and applicable federal
law.

 

SECTION 18. CASHLESS EXERCISE. The Committee also may allow
cashless exercises as permitted under Federal Reserve Board's Regulation T, subject to applicable securities law restrictions.
or by any other means which the Committee determines to be consistent with the Plan's purpose and applicable law. The proceeds
from such a payment shall be added to the general funds of the Company and shall be used for general corporate purposes.

 

ADOPTED as of the 21st day of February, 2009 by unanimous
consent of the Board of Directors.

 

    	12Advisory
Agreement

 

This
Advisory Agreement (“Agreement”) is made and entered into effective as of January 18, 2012, (the “Effective
Date”) by and between Arrayit Diagnostics, Inc., a Nevada corporation, (the “Company”), whose address is 1950
Cinnamon Teal Dr, Redmond, Oregon 97756, on its own behalf on the one hand and Dr. Eric Zuckerman on the other hand, a Michigan
resident, (the “Advisor”), whose address is 20210 Farmington Road, Livonia, MI 48152.

 

Recitals

 

A.The Company wishes to engage the services
of the Advisor to exclusively advise and consult with the Company on certain business and financial matters as set forth in this
Agreement.

 

B.The Advisor has extensive experience
in medicine and more particularly in the area of diagnosis of disease and is affiliated with others is similar disciplines. As
a result, the Advisor has the expertise to advise and assist the Company in selecting appropriate members for a medical advisory
board, and in evaluating businesses that may be likely candidates to strategically partner with the Company, on the terms and subject
to the conditions set forth in this Agreement.

 

C.The Company wishes to engage the services
of the Advisor as an independent contractor to exclusively advise and consult with it with respect to (i) developing a medical
advisory board, (ii) exploring strategic alliances, partnering opportunities and other cooperative ventures, (iii) evaluating possible
acquisition and strategic partnering candidates, and marketing opportunities for the Company, (iv) the Company’s business
development activities, including major geographic and service expansion plans, (v) the Company’s merger and acquisition
strategies, including the evaluation of targets and the structuring of transactions; (vi) the Company’s employee relations;
and (vii) the Company’s marketing strategy; and (viii) selecting appropriate financing from the available options and opportunities,
all on the terms and subject to the conditions set forth in this Agreement.

 

D.The Advisor is willing to accept such
engagement, on the terms set forth in this Agreement.

 

Now therefore, in consideration of the foregoing
recitals and the mutual covenants and obligations contained in this Agreement, including the payment of fees and other good and
valuable consideration contained herein, the parties agree as follows:

 

1. Engagement.

 

1.1.Engagement. The Company
hereby engage the Advisor to perform the Corporate Undertakings, as defined and set forth in paragraph 1.4, for the Term as defined
and set forth in paragraph 1.2, and the Advisor hereby accepts this engagement, on the terms and subject to the conditions set
forth in this Agreement

 

1.2.Term. The term of the Advisor’s
engagement under this Agreement shall be for the period beginning on the Effective Date and ending at the expiration of two years
from and after the date hereof unless terminated as provided in paragraph 4 below (the “Term”), or unless extended
by mutual consent.

 

1.3.Relationship. The relationship
between the Company and the Advisor created by this Agreement is that of independent contractor, and the Advisor is not and shall
not be deemed to be an employee of the Company for any purpose.

 

1.4.Corporate Undertakings.
The Company will not engage in any of the following activities without a prior evaluation and affirmative recommendation of Advisor,
solely for the Company’s benefit and not for the benefit of any third party:

 

(a)Development
of a medical advisory board for the Company.

 

(b)Strategic alliances, strategic partnering and
other cooperative ventures within and without the Company’s present industry segment.

 

    	 

    	 

    

 

	Arrayit Diagnostics, Inc. & Dr. Eric Zuckerman	Page 2 Advisory Agreement

 

(c)Acquisition
and marketing strategies.

 

(d)Business
development activities, including major geographic and service expansion plans.

 

(e)Merger
and acquisition opportunities, including the evaluation of targets and the structuring of transactions.

 

(f)Selecting appropriate financing from the available
options and opportunities

 

(h)Advising,
consult and consent with the Company’s board of directors (the “Board”) and executive officers with respect to
any of the above described matters.

 

1.5.No Capital Raising Services.
The Corporate Undertakings do not include (i) soliciting the offer or sale of securities in any capital-raising transaction, or
(ii) to directly or indirectly promote or maintain a market for any of the Company’s securities.

 

1.6.No Investment Advisory or Brokerage
Services; No Legal Services. The Corporate Undertakings do not include requiring the Advisor to engage in any activities for
which an investment advisor’s registration or license is required under the U.S. Investment Advisors Act of 1940, or under
any other applicable federal or state law; or for which a “broker’s” or “dealer’s” registration
or license is required under the U.S. Securities Exchange Act of 1934, or under any other applicable federal or state law. Advisor’s
work on this engagement shall not constitute the rendering of legal advice, or the providing of legal services, to the Company.
Accordingly, Advisor shall not express any legal opinions with respect to any matters affecting the Company. Advisor’s work
on this engagement shall not consist of effecting transactions in the Company’s securities and Advisor shall not provide
any securities broker-dealer services to the Company.

 

1.7.Location. The Company and
the Advisor intend that the Corporate Undertakings shall be rendered primarily from the Advisor’s offices in Livonia, Michigan
and may be rendered by telephone and e-mail communication. The Advisor understands and acknowledges it may be necessary to travel
to perform the Corporate Undertakings, and that the Advisor shall be required to do so at its own expense (the Advisor’s
Fee having been agreed to in consideration thereof). The Advisor shall be reasonably available by telephone to consult with the
Board at regular and special meetings thereof.

 

1.8.Time; Non-exclusive. The
Advisor shall devote as much time to the performance of the Corporate Undertakings as is reasonably necessary, but the Advisor
shall not be required to devote any fixed number of hours or days to the performance of the Corporate Undertakings. The Company
recognizes that the Advisor has and will continue to have other clients and business, and agrees that this engagement is non-exclusive.

 

1.9.Support Staff and Facilities.
The Advisor shall furnish its own support staff, office, telephone, and other facilities and equipment necessary to the performance
of the Corporate Undertakings, and the Company shall not be required to provide the Advisor with any such staff, facilities or
equipment.

 

1.10.Confidentiality. The Advisor
shall not disclose any non-public, confidential or proprietary information, including but not limited to confidential information
concerning the Company’s products, methods, engineering designs and standards, analytical techniques, technical information,
customer information, or employee information, unless required to do so by applicable law or pursuant to an effective non-disclosure
agreement.

 

2. Advisor’s Fees and Expenses.

 

2.1.The Advisor’s Fee.
The Advisor agrees to accept compensation for its services under this Agreement in the form of an equity interest in the Company.
Therefore, the Company shall issue and deliver to the Advisor, as a fee for its Corporate Undertakings under this Agreement (the
“Advisor’s Fee”):

 

    	 

    	 

    

 

	Arrayit Diagnostics, Inc. & Dr. Eric Zuckerman	Page 3 Advisory Agreement

 

(a)One Million
common shares (1,000,000) of the Company (Equity), which shall be fully earned and non-refundable in consideration of its execution
of this Agreement and the payment of $10. The Company shall issue certificates or other evidence representing the Equity in the
name or names specified from time to time by the Advisor in writing to the Company.

 

(b)The Company
shall issue instructions to its management to issue certificates representing the Equity, as directed by the Advisor, with the
right to be included in the next registration statement, to Advisor. The Company warrants that the Equity shall be freely transferable
on the books and records of the Company. Nothing in this Section 2.1(b) shall affect in any way the Advisor’s obligations
and agreement to comply with all applicable securities laws upon resale of the Equity.

 

2.2.Offset; Withholding; Taxes.
The Company shall pay the Advisor’s Fee to the Advisor without offset, deduction or withholding of any kind or for any purpose.
The Advisor shall pay any federal, state and local taxes payable by it with respect to the Advisor’s Fee.

 

2.3.The Advisor’s Expenses.
The Advisor shall pay all expenses incurred by it in connection with its performance of the Corporate Undertakings under this Agreement.

 

3.Representations, Warranties and Covenants:

 

3.1.Representations and Warranties
of the Company. The Company represents and warrants to and covenants with the Advisor that:

 

(a)Incorporation, Good Standing, and Due Qualification.
The Company is a corporation duly incorporated, validly existing and in good standing under the laws of Nevada; has the corporate
power and authority to own its assets and to transact the business in which engaged and proposes to be engaged in; and is duly
qualified as a foreign corporation and in good standing under the laws of each other jurisdiction in which such qualification is
required.

 

(b)Corporate Power and Authority. The execution,
delivery and performance by the Company of this Agreement, including the issuance of the Equity has been duly authorized by all
necessary corporate action and does not and will not (i) require any consent or approval of the Company’s shareholders; (ii)
contravene the Company’s certificate of incorporation or bylaws; (iii) violate any provision of any law, rule, regulation,
order, writ, judgment, injunction, decree, determination or award presently in effect having applicability to the Company; (iv)
result in a breach of or constitute a default under any agreement or other instrument to which the Company is a party.

 

(c)Legally Enforceable Agreement. This
Agreement is the, legal, valid and binding obligation of the Company, enforceable against it in accordance with its terms, except
to the extent that such enforcement may be limited by applicable bankruptcy, insolvency and other similar laws affecting creditors’
rights generally.

 

3.2.Representations and Warranties
of the Advisor. The Advisor represents and warrants to and covenants with the Company that:

 

(a)Power and Authority. The execution,
delivery and performance by the Advisor of this Agreement, does not and will not (i) violate any provision of any law, rule, regulation,
order, writ, judgment, injunction, decree, determination or award presently in effect having applicability to the Advisor; (ii)
result in a breach of or constitute a default under any agreement or other instrument to which the Advisor is a party.

 

(b)Power and Authority. The execution,
delivery and performance by the Advisor of this Agreement, have been duly authorized by all necessary action and do not and will
not (i) require any consent or approval of the Advisor’s members; (ii) contravene the Advisor’s organizational documents;
(iii) violate any provision of any law, rule, regulation, order, writ, judgment, injunction, decree, determination or award presently
in effect having applicability to the Advisor; (iv) result in a breach of or constitute a default under any agreement or other
instrument to which the Advisor is a party.

 

    	 

    	 

    

 

	Arrayit Diagnostics, Inc. & Dr. Eric Zuckerman	Page 4 Advisory Agreement

 

(c)Legally Enforceable Agreement. This
Agreement is the, legal, valid and binding obligation of the Advisor, enforceable against it in accordance with its terms, except
to the extent that such enforcement may be limited by applicable bankruptcy, insolvency and other similar laws affecting creditors’
rights generally.

 

4.Termination. This Agreement may not be terminated
prior to the expiration of the Term:

 

5.Confidential Information.

 

5.1.The parties hereto
recognize that a major need of the Company is to preserve its specialized knowledge, trade secrets, and confidential information.
The strength and good will of the Company is derived from the specialized knowledge, trade secrets, and confidential information
generated from experience with the activities undertaken by the Company. The disclosure of this information and knowledge to competitors
would be beneficial to them and detrimental to the Company, as would the disclosure of information about the marketing practices,
pricing practices, costs, profit margins, design specifications, analytical techniques, and similar items of the Company. By reason
of being a Advisor to the Company, Advisor has or will have access to, and will obtain, specialized knowledge, trade secrets and
confidential information about the Company’s operations, which operations extend through the United States. Therefore, Advisor
recognizes that the Company is relying on these agreements in entering into this Agreement:

 

5.2 During and after
the Term, Advisor will not use, disclose to others, or publish any inventions or any confidential business information about the
affairs of the Company, including but not limited to confidential information concerning the Company’s products, methods,
engineering designs and standards, analytical techniques, technical information, customer information, employee information, and
other confidential information acquired by him in the course of his past or future services for the Company. Advisor agrees to
hold as the Company’s property all memoranda, books, papers, letters, formulas and other data, and all copies thereof and
therefrom, in any way relating to the Company’s business and affairs, whether made by him or otherwise coming into his possession,
and on termination of this agreement, or on demand of the Company, at any time, to deliver the same to the Company within twenty
four hours of such termination or demand.

 

5.3 During the Term,
Advisor will not induce any employee of the Company to leave the Company’s employ or hire any such employee (unless the Board
of Directors of the Company shall have authorized such employment and the Company shall have consented thereto in writing).

 

6.General Provisions.

 

6.1.Entire Agreement; Modification;
Waivers. This Agreement contains the entire agreement of the parties, and supersedes any prior agreements with respect to its
subject matter. There are no agreements, understandings or arrangements of the parties with respect to the subject matter of this
Agreement that are not contained herein. This Agreement shall not be modified except by an instrument in writing signed by the
parties. No waiver of any provision of this Agreement shall be effective unless made in writing and signed by the party making
the waiver. The waiver of any provision of this Agreement shall not be deemed to be a waiver of any other provision or any future
waiver of the same provision.

6.2. Notices. All notices given
under this Agreement shall be in writing, addressed to the parties as set forth in the first paragraph hereof, and shall be effective
on the earliest of (i) the date received, or (ii) on the second business day after delivery to a major international air delivery
or air courier service (such as Federal Express or Network Couriers).

 

6.3.Governing
Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Nevada; provided,
however, that if any provision of this Agreement is unenforceable under such law but is enforceable under the laws of the State
of Nevada, then Texas law shall govern the construction and enforcement of that provision.

  

    	 

    	 

    

  

	Arrayit Diagnostics, Inc. & Dr. Eric Zuckerman	Page5  Advisory Agreement

  

6.4. Jurisdiction and Venue.
The courts of the State of Texas sitting in Harris County (the “Harris County Courts”) shall have exclusive jurisdiction
to hear, adjudicate, decide, determine and enter final judgment in any action, suit, proceeding, case, controversy or dispute,
whether at law or in equity or both, and whether in contract or tort or both, arising out of or related to this Agreement, or the
construction or enforcement hereof or thereof (any such action, suit, proceeding, case, controversy or dispute a "Related
Action"). The Company and the Advisor hereby irrevocably consent and submit to the exclusive personal jurisdiction of the
Harris County Courts to hear, adjudicate, decide, determine and enter final judgment in any Related Action. The Company and the
Advisor hereby irrevocably waive and agree not to assert any right or claim that it is not personally subject to the jurisdiction
of the Harris County Courts in any Related Action, including any claim of forum non conveniens or that the Harris County
Courts are not the proper venue or form to adjudicate any Related Action. If any Related Action is brought or maintained in any
court other than the Harris County Courts, then that court shall, at the request of the Company or the Advisor, dismiss that action.
The parties may enter a judgment rendered by the Harris County Courts under this Agreement for enforcement in the courts of Nevada
and the party against whom such judgment is taken will lot contest the authority of such courts to enforce such a judgment.

 

6.5.
Waiver of Jury Trial. The Company and the Advisor hereby waive trial by jury in any Related Action.

 

6.6Attorney's Fees. The prevailing
party in any Related Action shall be entitled to recover that party's costs of suit, including reasonable attorney's fees.

 

6.7Binding Effect. This Agreement
shall be binding on, and shall inure to the benefit of the parties and their respective successors in interest.

 

6.8 Construction, Counterparts. This
Agreement shall be construed as a whole and in favor of he validity and enforceability of each of its provisions, so as to carry
out the intent of the parties as expressed herein, Heading are for the convenience of reference, and the meaning and interpretation
of the text of any provision shall take precedence over its heading. This Agreement may be signed in one or more counterparts,
each of wihch shall constitute an original, but all of which, taken together shall constitute one agreement. A faxed copy or photocopy
of a party's signature shall be deemed an original for all purposes.

 

In
Witness Whereof, the parties have executed this Agreement effective as of the Effective Date

 

	The Company:	The Advisor:
	 	 
	ARRAYIT DIAGNOSTICS, INC.	ERIC ZUCKERMAN, DO
	 	 
	By:	/s/ John Howell	 	By:	/s/ Eric Zuckerman, Do
	 	John Howell, President & CEO	 	Eric Zuckerman, Do

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]